Carla Oliveira

List of Publications by Year
in descending order

184 papers	16,695 citations	20759 60 h-index	16127 124 g-index
192 all docs	192 docs citations	192 times ranked	21003 citing authors

#	ARTICLE	IF	CITATIONS
1	Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015, 4, 27066.	5.5	3,973
2	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	3.4	540
3	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	1.5	495
4	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline<i>CDH1</i>mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	1.5	479
5	Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology, 2001, 121, 823-829.	0.6	402
6	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10, 3886-3899.	7.3	397
7	Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2360.	3.8	394
8	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nature Genetics, 2009, 41, 365-370.	9.4	355
9	Familial gastric cancer: overview and guidelines for management. Journal of Medical Genetics, 1999, 36, 873-80.	1.5	344
10	The prevalence of PIK3CA mutations in gastric and colon cancer. European Journal of Cancer, 2005, 41, 1649-1654.	1.3	314
11	Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncology, The, 2015, 16, e60-e70.	5.1	311
12	E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene, 2001, 20, 1525-1528.	2.6	252
13	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	5.1	237
14	The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nature Communications, 2018, 9, 490.	5.8	198
15	Germline CDH1 deletions in hereditary diffuse gastric cancer families. Human Molecular Genetics, 2009, 18, 1545-1555.	1.4	185
16	Anti-miRNA oligonucleotides: A comprehensive guide for design. RNA Biology, 2018, 15, 338-352.	1.5	172
17	Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Human Molecular Genetics, 2003, 12, 575-582.	1.4	167
18	Guidelines for the Liâ€“Fraumeni and heritable TP53-related cancer syndromes. European Journal of Human Genetics, 2020, 28, 1379-1386.	1.4	167

#	Article	IF	Citations
19	KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene, 2007, 26, 158-163.	2.6	164
20	Germline E-cadherin mutations in familial lobular breast cancer. Journal of Medical Genetics, 2007, 44, 726-731.	1.5	162
21	Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. Journal of Medical Genetics, 2005, 43, 138-142.	1.5	161
22	BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene, 2005, 24, 3995-3998.	2.6	155
23	Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Human Mutation, 2002, 19, 510-517.	1.1	153
24	Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 367-378.	1.4	148
25	Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer. Journal of Clinical Oncology, 2013, 31, 868-875.	0.8	145
26	The Clinicopathological Features of Gastric Carcinomas with Microsatellite Instability May Be Mediated by Mutations of Different â€œTarget Genesâ€. American Journal of Pathology, 1998, 153, 1211-1219.	1.9	144
27	Quantification of Epigenetic and Genetic 2nd Hits in CDH1 During Hereditary Diffuse Gastric Cancer Syndrome Progression. Gastroenterology, 2009, 136, 2137-2148.	0.6	142
28	Genetics, Pathology, and Clinics of Familial Gastric Cancer. International Journal of Surgical Pathology, 2006, 14, 21-33.	0.4	141
29	Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline <i>CDH1</i> sequence variants. Human Mutation, 2018, 39, 1553-1568.	1.1	138
30	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	3.3	137
31	BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene, 2003, 22, 9192-9196.	2.6	132
32	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13, 2303-2311.	1.4	127
33	Lack of microRNAâ€101 causes Eâ€cadherin functional deregulation through EZH2 upâ€regulation in intestinal gastric cancer. Journal of Pathology, 2012, 228, 31-44.	2.1	125
34	BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer, 2008, 8, 255.	1.1	124
35	Mechanisms and sequelae of Eâ€cadherin silencing in hereditary diffuse gastric cancer. Journal of Pathology, 2008, 216, 295-306.	2.1	122
36	<i>CDH1</i>â€related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376.	2.3	110

#	Article	IF	Citations
37	Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. Pathobiology, 2018, 85, 50-63.	1.9	101
38	Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Human Molecular Genetics, 2010, 19, 943-952.	1.4	100
39	E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. European Journal of Cancer, 2004, 40, 1897-1903.	1.3	97
40	Gastric cancer: adding glycosylation to the equation. Trends in Molecular Medicine, 2013, 19, 664-676.	3.5	95
41	CDX2 regulation by the RNA-binding protein MEX3A: impact on intestinal differentiation and stemness. Nucleic Acids Research, 2013, 41, 3986-3999.	6.5	94
42	Loss and Recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation Is a Mechanism Involved in Epithelial-Mesenchymal-Epithelial Transitions. PLoS ONE, 2012, 7, e33191.	1.1	93
43	Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene, 2004, 23, 2236-2240.	2.6	92
44	Oncogenic mutations in gastric cancer with microsatellite instability. European Journal of Cancer, 2011, 47, 443-451.	1.3	92
45	3D Cellular Architecture Affects MicroRNA and Protein Cargo of Extracellular Vesicles. Advanced Science, 2019, 6, 1800948.	5.6	91
46	Loss of Heterozygosity and Promoter Methylation, but not Mutation, May Underlie Loss of TFF1 in Gastric Carcinoma. Laboratory Investigation, 2002, 82, 1319-1326.	1.7	88
47	ActivatedBRAFtargets proximal colon tumors with mismatch repair deficiency andMLH1inactivation. Genes Chromosomes and Cancer, 2004, 39, 138-142.	1.5	87
48	Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. Journal of Clinical Pathology, 2007, 61, 25-30.	1.0	83
49	The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. Oncogene, 2008, 27, 4255-4260.	2.6	83
50	E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Human Molecular Genetics, 2003, 12, 3007-3016.	1.4	79
51	Eâ€cadherin dysfunction in gastric cancer â€•Cellular consequences, clinical applications and open questions. FEBS Letters, 2012, 586, 2981-2989.	1.3	74
52	E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. European Journal of Cancer, 2011, 47, 631-639.	1.3	69
53	Specific Clinical and Biological Features Characterize Inflammatory Bowel Diseaseâ€“Associated Colorectal Cancers Showing Microsatellite Instability. Journal of Clinical Oncology, 2007, 25, 4231-4238.	0.8	68
54	Hereditary gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 147-157.	1.0	66

#	Article	IF	Citations
55	De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Laboratory Investigation, 2010, 90, 1604-1614.	1.7	66
56	B-RafV600E Cooperates With Alternative Spliced Rac1b to Sustain Colorectal Cancer Cell Survival. Gastroenterology, 2008, 135, 899-906.	0.6	65
57	MSI phenotype and MMR alterations in familial and sporadic gastric cancer. International Journal of Cancer, 2011, 128, 1606-1613.	2.3	65
58	tRNA Deregulation and Its Consequences inÂCancer. Trends in Molecular Medicine, 2019, 25, 853-865.	3.5	63
59	1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Research, 2012, 32, 249-57.	0.5	63
60	Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. Human Molecular Genetics, 2008, 17, 3566-3576.	1.4	62
61	Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the antiâ€tumour therapeutic approach with doxorubicin. Journal of Extracellular Vesicles, 2016, 5, 32538.	5.5	62
62	Cancer syndromes and therapy by stop-codon readthrough. Trends in Molecular Medicine, 2012, 18, 667-678.	3.5	61
63	Monoclonal antibodies: technologies for early discovery and engineering. Critical Reviews in Biotechnology, 2018, 38, 394-408.	5.1	61
64	Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1928-1939.	1.8	60
65	Germline Mutations in MAP3K6 Are Associated with Familial Gastric Cancer. PLoS Genetics, 2014, 10, e1004669.	1.5	57
66	Colorectal cancer and RASSF familyâ€"A special emphasis on RASSF1A. International Journal of Cancer, 2013, 132, 251-258.	2.3	54
67	Promoter methylation of TGF? receptor I and mutation of TGF? receptor II are frequent events in MSI sporadic gastric carcinomas. Journal of Pathology, 2003, 200, 32-38.	2.1	53
68	BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying <i>BRAF</i>^{<i>V</i>600<i>E</i>} but not <i>KRAS</i> mutations. Journal of Pathology, 2008, 214, 320-327.	2.1	53
69	E-Cadherin Destabilization Accounts for the Pathogenicity of Missense Mutations in Hereditary Diffuse Gastric Cancer. PLoS ONE, 2012, 7, e33783.	1.1	53
70	A 3D in vitro model to explore the inter-conversion between epithelial and mesenchymal states during EMT and its reversion. Scientific Reports, 2016, 6, 27072.	1.6	53
71	E-Cadherin Alterations in Hereditary Disorders with Emphasis on Hereditary Diffuse Gastric Cancer. Progress in Molecular Biology and Translational Science, 2013, 116, 337-359.	0.9	52
72	Antibodies and associates: Partners in targeted drug delivery. , 2017, 177, 129-145.		52

#	Article	IF	Citations
73	Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut, 2010, 59, 1516-1526.	6.1	51
74	CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. International Journal of Cancer, 2002, 101, 196-197.	2.3	50
75	Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. Advances in Experimental Medicine and Biology, 2016, 908, 371-391.	0.8	47
76	Genetic screening for hereditary diffuse gastric cancer. Expert Review of Molecular Diagnostics, 2003, 3, 201-215.	1.5	46
77	Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene, 2005, 24, 7630-7634.	2.6	45
78	Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology, 2018, 73, 878-886.	1.6	45
79	Hereditary gastric cancer: whatâ€™s new? Update 2013â€“2018. Familial Cancer, 2019, 18, 363-367.	0.9	44
80	MSI-L Gastric Carcinomas Share the hMLH1 Methylation Status of MSI-H Carcinomas but Not Their Clinicopathological Profile. Laboratory Investigation, 2000, 80, 1915-1923.	1.7	43
81	Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. European Journal of Cancer, 2003, 39, 1222-1227.	1.3	43
82	<i>CPEB1</i>, a novel gene silenced in gastric cancer: a<i>Drosophila</i>approach. Gut, 2012, 61, 1115-1123.	6.1	41
83	Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. Gastrointestinal Endoscopy, 2018, 87, 1566-1575.	0.5	41
84	New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer, 2019, 22, 77-90.	2.7	41
85	Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. European Journal of Surgical Oncology, 2007, 33, 1061-1067.	0.5	40
86	Hereditary diffuse gastric cancer â€“ Pathophysiology and clinical management. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 1055-1068.	1.0	40
87	Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis, 2005, 26, 923-930.	1.3	39
88	Molecular Characterization of ESBL-Producing Enterobacteriaceae in Northern Portugal. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	39
89	Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. Acta Biomaterialia, 2018, 81, 208-218.	4.1	39
90	Colorectal cancer-related mutant <i>KRAS</i> alleles function as positive regulators of autophagy. Oncotarget, 2015, 6, 30787-30802.	0.8	39

#	Article	IF	Citations
91	Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 181-184.	1.4	38
92	Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation. Cancer Letters, 2006, 242, 191-197.	3.2	37
93	Role of germline aberrations affecting <i>CTNNA1</i>, <i>MAP3K6</i> and <i>MYD88</i> in gastric cancer susceptibility. Journal of Medical Genetics, 2018, 55, 669-674.	1.5	37
94	E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in Drosophila epithelia. Human Molecular Genetics, 2006, 15, 1704-1712.	1.4	35
95	Genetic Screening for Familial Gastric Cancer. Hereditary Cancer in Clinical Practice, 2004, 2, 51.	0.6	34
96	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	1.4	34
97	Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. European Journal of Human Genetics, 2021, 29, 1337-1347.	1.4	34
98	Adsorbed Fibrinogen Enhances Production of Bone- and Angiogenic-Related Factors by Monocytes/Macrophages. Tissue Engineering - Part A, 2014, 20, 250-263.	1.6	33
99	Insulin/IGF-I Signaling Pathways Enhances Tumor Cell Invasion through Bisecting GlcNAc N-glycans Modulation. An Interplay with E-Cadherin. PLoS ONE, 2013, 8, e81579.	1.1	33
100	Proteomics Analysis of Gastric Cancer Patients with Diabetes Mellitus. Journal of Clinical Medicine, 2021, 10, 407.	1.0	32
101	Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology, 2008, 25, 274-287.	1.0	30
102	Codon misreading tRNAs promote tumor growth in mice. RNA Biology, 2018, 15, 1-14.	1.5	30
103	Genetics of gastric cancer: what do we know about the genetic risks?. Translational Gastroenterology and Hepatology, 2019, 4, 55-55.	1.5	30
104	Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. Molecular Oncology, 2021, 15, 2841-2867.	2.1	27
105	Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Human Molecular Genetics, 2010, 19, 697-706.	1.4	26
106	Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation. Scientific Reports, 2016, 6, 34860.	1.6	26
107	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. International Journal of Molecular Sciences, 2018, 19, 2079.	1.8	26
108	CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells. Cells, 2019, 8, 276.	1.8	26

#	Article	IF	Citations
109	Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer. International Journal of Cancer, 2017, 141, 1478-1489.	2.3	24
110	Effective intracellular delivery of bevacizumab <i>via</i> PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells. Biomaterials Science, 2020, 8, 3720-3729.	2.6	24
111	Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). European Journal of Human Genetics, 2013, 21, 891-891.	1.4	22
112	Frequent ki-ras mutations in gastric tumors of the MSI phenotype. Gastroenterology, 2003, 125, 1282-1283.	0.6	21
113	Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 1187-1201.	1.5	21
114	Cancer predisposition and germline CTNNA1 variants. European Journal of Medical Genetics, 2021, 64, 104316.	0.7	21
115	CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling. Integrative Biology (United Kingdom), 2018, 10, 145-158.	0.6	20
116	Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives. Journal of Medical Genetics, 2021, 58, 1-11.	1.5	20
117	Molecular cloning and analysis of SSc5D, a new member of the scavenger receptor cysteine-rich superfamily. Molecular Immunology, 2009, 46, 2585-2596.	1.0	19
118	Extracellular Vesicles Ã¢â,¬â€œ Powerful Markers of Cancer EVolution. Frontiers in Immunology, 2014, 5, 685.	2.2	19
119	Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. Cancers, 2019, 11, 1340.	1.7	19
120	A Fast Alternative to Soft Lithography for the Fabrication of Organâ€onâ€aâ€Chip Elastomericâ€Based Devices and Microactuators. Advanced Science, 2021, 8, 2003273.	5.6	19
121	ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPÂ in CDH3 gene activation. Human Molecular Genetics, 2010, 19, 2554-2566.	1.4	18
122	The mechanisms underlying MMR deficiency in immunodeficiencyâ€related nonâ€Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. International Journal of Cancer, 2009, 125, 2360-2366.	2.3	17
123	Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. European Journal of Human Genetics, 2014, 22, 1085-1092.	1.4	17
124	Lewis enzyme (Î±1â€"3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. Journal of Human Genetics, 2003, 48, 183-189.	1.1	16
125	MBD4 mutations are rare in gastric carcinomas with microsatellite instability. Cancer Genetics and Cytogenetics, 2003, 145, 103-107.	1.0	16
126	<i>KRAS</i> Mutations and Antiâ€"Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases. Journal of Clinical Oncology, 2009, 27, 158-159.	0.8	16

#	Article	IF	Citations
127	Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesisâ€. Human Molecular Genetics, 2012, 21, 4253-4269.	1.4	16
128	Impact of surfactants on the target recognition of Fab-conjugated PLGA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 366-370.	2.0	16
129	Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. BMC Molecular Biology, 2018, 19, 6.	3.0	16
130	S100P is a molecular determinant of E-cadherin function in gastric cancer. Cell Communication and Signaling, 2019, 17, 155.	2.7	16
131	Germline TP53 Testing in Breast Cancers: Why, When and How?. Cancers, 2020, 12, 3762.	1.7	16
132	Pathology and Genetics of Familial Gastric Cancer. International Journal of Surgical Pathology, 2010, 18, 33-36.	0.4	15
133	Human cells adapt to translational errors by modulating protein synthesis rate and protein turnover. RNA Biology, 2020, 17, 135-149.	1.5	15
134	A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 619-626.	1.4	14
135	TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. Familial Cancer, 2009, 8, 383-390.	0.9	14
136	Bioengineering a novel 3D in vitro model of gastric mucosa for stomach permeability studies. Acta Biomaterialia, 2018, 82, 68-78.	4.1	14
137	Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Scientific Reports, 2019, 9, 10362.	1.6	14
138	Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells. Cancers, 2020, 12, 858.	1.7	14
139	<i>CDX2</i> promoter methylation is not associated with mRNA expression. International Journal of Cancer, 2009, 125, 1739-1742.	2.3	13
140	KRAS Signaling Pathway Alterations in Microsatellite Unstable Gastrointestinal Cancers. Advances in Cancer Research, 2010, 109, 123-143.	1.9	13
141	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Familial Cancer, 2016, 15, 289-296.	0.9	13
142	Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer. Cancers, 2020, 12, 70.	1.7	13
143	Unmasking the role of<i>KRAS</i>and<i>BRAF</i>pathways in MSI colorectal tumors. Expert Review of Gastroenterology and Hepatology, 2009, 3, 5-9.	1.4	12
144	CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. BMC Cancer, 2019, 19, 69.	1.1	12

#	Article	IF	Citations
145	Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer. Pharmaceuticals, 2021, 14, 457.	1.7	12
146	Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells. Nanomaterials, 2021, 11, 295.	1.9	11
147	Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. International Journal of Gynecological Cancer, 2008, 18, 1234-1247.	1.2	10
148	New Target Genes in Endometrial Tumors Show a Role for the Estrogen-Receptor Pathway in Microsatellite-Unstable Cancers. Human Mutation, 2014, 35, 1514-1523.	1.1	10
149	Optimizing the management of hereditary haemochromatosis: the value of <scp>MRI</scp> R2* quantification to predict and monitor body iron stores. British Journal of Haematology, 2018, 183, 491-493.	1.2	10
150	Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. European Journal of Medical Genetics, 2022, 65, 104401.	0.7	10
151	Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2. Scientific Reports, 2015, 5, 10079.	1.6	9
152	The Dysfunctional Immune System in Common Variable Immunodeficiency Increases the Susceptibility to Gastric Cancer. Cells, 2020, 9, 1498.	1.8	9
153	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358.	1.4	9
154	Gastric Cancer Extracellular Vesicles Tune the Migration and Invasion of Epithelial and Mesenchymal Cells in a Histotype-Dependent Manner. International Journal of Molecular Sciences, 2019, 20, 2608.	1.8	8
155	The effects of L-carnitine supplementation in athletic performance. Science and Sports, 2019, 34, 63-72.	0.2	8
156	Whole Slide Image Registration for the Study of Tumor Heterogeneity. Lecture Notes in Computer Science, 2018, , 95-102.	1.0	7
157	Skipping Exon-v6 from CD44v6-Containing Isoforms Influences Chemotherapy Response and Self-Renewal Capacity of Gastric Cancer Cells. Cancers, 2020, 12, 2378.	1.7	7
158	tRNAs as a Driving Force of Genome Evolution in Yeast. Frontiers in Microbiology, 2021, 12, 634004.	1.5	7
159	The CDH1 c.1901C>T Variant: A Founder Variant in the Portuguese Population with Severe Impact in mRNA Splicing. Cancers, 2021, 13, 4464.	1.7	7
160	Different Types of Epithelial Cadherin Alterations Play Different Roles in Human Carcinogenesis. Advances in Anatomic Pathology, 2002, 9, 329-337.	2.4	6
161	Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators. European Journal of Human Genetics, 2012, 20, 878-883.	1.4	6
162	Familial gastric carcinoma. Diagnostic Histopathology, 2014, 20, 239-246.	0.2	6

#	Article	IF	Citations
163	KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 383-392.	1.4	6
164	Comparison of Eastâ€Asia and Westâ€Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness. International Journal of Cancer, 2022, 150, 868-880.	2.3	6
165	Upregulation of tRNA-Ser-AGA-2-1 Promotes Malignant Behavior in Normal Bronchial Cells. Frontiers in Molecular Biosciences, 2022, 9, 809985.	1.6	6
166	Rotary orbital suspension culture of embryonic stem cell-derived neural stem/progenitor cells: impact of hydrodynamic culture on aggregate yield, morphology and cell phenotype. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 2227-2240.	1.3	5
167	Towards Automatic Protein Co-Expression Quantification in Immunohistochemical TMA Slides. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 393-402.	3.9	5
168	The role of non-standard translation in <i>Candida albicans</i> pathogenesis. FEMS Yeast Research, 2021, 21, .	1.1	5
169	Immunophenotype of Gastric Tumors Unveils a Pleiotropic Role of Regulatory T Cells in Tumor Development. Cancers, 2021, 13, 421.	1.7	5
170	Reply to Kratz et al.. European Journal of Human Genetics, 2020, 28, 1483-1485.	1.4	4
171	CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients. Biomedicines, 2021, 9, 1249.	1.4	3
172	Epithelial-Mesenchymal Plasticity Induced by Discontinuous Exposure to TGFÎ²1 Promotes Tumour Growth. Biology, 2022, 11, 1046.	1.3	3
173	Hereditary Cancer Risk Assessment: Challenges for the Next-Gen Sequencing Era. Frontiers in Oncology, 2015, 5, 62.	1.3	2
174	Risk-reducing total gastrectomy in asymptomatic CDH1 carriers. European Surgery - Acta Chirurgica Austriaca, 2020, 52, 171-178.	0.3	2
175	E-Cadherin Germline Mutations. , 2013, , 35-49.		2
176	CDH1 structural alterations as novel prognostic biomarker in gastric cancer patients.. Journal of Clinical Oncology, 2011, 29, 42-42.	0.8	2
177	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€" a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	0.7	2
178	Updated perspective and directions on hereditary diffuse gastric cancer. , 2021, , 217-258.		1
179	Level of literacy and clinical outcomes in patients with Chagas disease: SaMi-Trop project. European Journal of Public Health, 2020, 30, .	0.1	1
180	Hereditary Diffuse Gastric Cancer and Other Gastric Cancers Associated with Hereditary Predisposition Syndromes. Molecular Pathology Library, 2013, , 83-107.	0.1	0

#	Article	IF	Citations
181	Inherited CDH1 pathogenic variant: is there a place for surveillance of esophageal gastric inlet patch?. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482091639.	1.4	0
182	PIK3CA Gene Alterations in Human Cancers. , 2009, , 1-20.		0
183	Non-CDH1-Associated Familial Gastric Cancer and Epigenetics Factors. , 2013, , 111-125.		0
184	Alternative Mechanisms to Germline CDH1 Mutations in Hereditary Diffuse Gastric Cancer. , 2013, , 87-96.		0